Compile Data Set for Download or QSAR
maximum 50k data
Found 137 of ph data with Target = 'Vascular endothelial growth factor receptor 3'
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty

US Patent
LigandPNGBDBM202392(US9238644, 1)
Affinity DataIC50:  173nMpH: 7.2 T: 2°CAssay Description:Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well pl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty

US Patent
LigandPNGBDBM202398(US9238644, 5 | US9238644, 68)
Affinity DataIC50:  51nMpH: 7.2 T: 2°CAssay Description:Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well pl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty

US Patent
LigandPNGBDBM202393(US9238644, 1-2A)
Affinity DataIC50:  315nMpH: 7.2 T: 2°CAssay Description:Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well pl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty

US Patent
LigandPNGBDBM202395(US9238644, 2)
Affinity DataIC50:  26nMpH: 7.2 T: 2°CAssay Description:Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well pl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty

US Patent
LigandPNGBDBM202396(US9238644, 3)
Affinity DataIC50:  27nMpH: 7.2 T: 2°CAssay Description:Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well pl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty

US Patent
LigandPNGBDBM202397(US9238644, 4)
Affinity DataIC50:  38nMpH: 7.2 T: 2°CAssay Description:Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well pl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty

US Patent
LigandPNGBDBM202398(US9238644, 5 | US9238644, 68)
Affinity DataIC50:  51nMpH: 7.2 T: 2°CAssay Description:Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well pl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty

US Patent
LigandPNGBDBM202399(US9238644, 6)
Affinity DataIC50:  17nMpH: 7.2 T: 2°CAssay Description:Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well pl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty

US Patent
LigandPNGBDBM202400(US9238644, 7)
Affinity DataIC50:  38nMpH: 7.2 T: 2°CAssay Description:Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well pl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty

US Patent
LigandPNGBDBM202401(US9238644, 8)
Affinity DataIC50:  19nMpH: 7.2 T: 2°CAssay Description:Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well pl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty

US Patent
LigandPNGBDBM202402(BDBM202403 | US9238644, 9)
Affinity DataIC50:  75nMpH: 7.2 T: 2°CAssay Description:Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well pl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty

US Patent
LigandPNGBDBM202405(US9238644, 12)
Affinity DataIC50:  267nMpH: 7.2 T: 2°CAssay Description:Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well pl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty

US Patent
LigandPNGBDBM202406(US9238644, 13)
Affinity DataIC50:  9nMpH: 7.2 T: 2°CAssay Description:Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well pl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty

US Patent
LigandPNGBDBM202407(US9238644, 14)
Affinity DataIC50:  30nMpH: 7.2 T: 2°CAssay Description:Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well pl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty

US Patent
LigandPNGBDBM202408(US9238644, 15)
Affinity DataIC50:  51nMpH: 7.2 T: 2°CAssay Description:Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well pl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty

US Patent
LigandPNGBDBM202409(US9238644, 16)
Affinity DataIC50:  4nMpH: 7.2 T: 2°CAssay Description:Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well pl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty

US Patent
LigandPNGBDBM202410(US9238644, 17)
Affinity DataIC50:  62nMpH: 7.2 T: 2°CAssay Description:Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well pl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty

US Patent
LigandPNGBDBM202411(US9238644, 18)
Affinity DataIC50:  5nMpH: 7.2 T: 2°CAssay Description:Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well pl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty

US Patent
LigandPNGBDBM202412(US9238644, 19)
Affinity DataIC50:  11nMpH: 7.2 T: 2°CAssay Description:Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well pl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty

US Patent
LigandPNGBDBM202413(US9238644, 20)
Affinity DataIC50:  38nMpH: 7.2 T: 2°CAssay Description:Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well pl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty

US Patent
LigandPNGBDBM202414(US9238644, 21)
Affinity DataIC50:  14nMpH: 7.2 T: 2°CAssay Description:Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well pl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty

US Patent
LigandPNGBDBM202417(US9238644, 24)
Affinity DataIC50:  25nMpH: 7.2 T: 2°CAssay Description:Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well pl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty

US Patent
LigandPNGBDBM202429(US9238644, 35)
Affinity DataIC50:  64nMpH: 7.2 T: 2°CAssay Description:Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well pl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty

US Patent
LigandPNGBDBM202430(US9238644, 36)
Affinity DataIC50:  76nMpH: 7.2 T: 2°CAssay Description:Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well pl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty

US Patent
LigandPNGBDBM202438(US9238644, 44)
Affinity DataIC50:  52nMpH: 7.2 T: 2°CAssay Description:Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well pl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty

US Patent
LigandPNGBDBM202440(US9238644, 45)
Affinity DataIC50:  23nMpH: 7.2 T: 2°CAssay Description:Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well pl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty

US Patent
LigandPNGBDBM202446(US9238644, 51)
Affinity DataIC50:  526nMpH: 7.2 T: 2°CAssay Description:Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well pl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty

US Patent
LigandPNGBDBM202481(US9238644, 56)
Affinity DataIC50:  68nMpH: 7.2 T: 2°CAssay Description:Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well pl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty

US Patent
LigandPNGBDBM202479(US9238644, 57)
Affinity DataIC50:  27nMpH: 7.2 T: 2°CAssay Description:Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well pl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty

US Patent
LigandPNGBDBM202478(US9238644, 57-1A)
Affinity DataIC50:  38nMpH: 7.2 T: 2°CAssay Description:Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well pl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty

US Patent
LigandPNGBDBM202455(US9238644, 57-2A)
Affinity DataIC50:  19nMpH: 7.2 T: 2°CAssay Description:Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well pl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty

US Patent
LigandPNGBDBM202462(US9238644, 64)
Affinity DataIC50:  394nMpH: 7.2 T: 2°CAssay Description:Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well pl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty

US Patent
LigandPNGBDBM202483(US9238644, 1-1A)
Affinity DataIC50:  329nMpH: 7.2 T: 2°CAssay Description:Adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLyAD) (Cat# CC-2810, Lonza) were seeded into clear-bottom, TC treated 12 well pl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty

US Patent
LigandPNGBDBM21079(1-[4-(3-amino-1H-indazol-4-yl)phenyl]-3-(2-fluoro-...)
Affinity DataKd:  16nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In DepthDetails PCBioAssay
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty

US Patent
LigandPNGBDBM24773(AMG 706 | AMG-706 | Motesanib | N-(3,3-dimethyl-1,...)
Affinity DataKd:  9.70nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In DepthDetails PCBioAssay
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty

US Patent
LigandPNGBDBM31085(1-[4-[(4-ethyl-1-piperazinyl)methyl]-3-(trifluorom...)
Affinity DataKd:  120nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In DepthDetails PCBioAssay
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty

US Patent
LigandPNGBDBM13533(1-[2-(4-methylphenyl)-5-tert-butyl-pyrazol-3-yl]-3...)
Affinity DataKd:  7.10E+3nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In DepthDetails PCBioAssay
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty

US Patent
LigandPNGBDBM25118((3Z)-4-amino-5-fluoro-3-[5-(4-methylpiperazino)-1,...)
Affinity DataKd:  580nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In DepthDetails PCBioAssay
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty

US Patent
LigandPNGBDBM31088(1-methyl-5-[2-[5-(trifluoromethyl)-1H-imidazol-2-y...)
Affinity DataKd:  2.00E+3nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In DepthDetails PCBioAssay
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty

US Patent
LigandPNGBDBM5446(CHEMBL553 | ERLOTINIB HYDROCHLORIDE | Erlotinib | ...)
Affinity DataKd:  2.10E+3nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In DepthDetails PCBioAssay
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty

US Patent
LigandPNGBDBM26474(5-({4-[(2,3-dimethyl-2H-indazol-6-yl)(methyl)amino...)
Affinity DataKd:  27nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In DepthDetails PCBioAssayDrugBank

TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty

US Patent
LigandPNGBDBM6866(1-Acyl-1H-[1,2,4]triazole-3,5-diamine Analogue 3b ...)
Affinity DataKd:  1.10E+3nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In DepthDetails PCBioAssay
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty

US Patent
LigandPNGBDBM31093(4-[[7-[2,6-bis(fluoranyl)phenyl]-9-chloranyl-5H-py...)
Affinity DataKd:  3.10E+3nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In DepthDetails PCBioAssay
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty

US Patent
LigandPNGBDBM31094(PKC-412 | cid_24202429)
Affinity DataKd:  670nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In DepthDetails PCBioAssay
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty

US Patent
LigandPNGBDBM4851((4-chlorophenyl)-[4-(4-pyridylmethyl)phthalazin-1-...)
Affinity DataKd:  330nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In DepthDetails PCBioAssay
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty

US Patent
LigandPNGBDBM31095(5-[(Z)-(5-fluoranyl-2-oxidanylidene-1H-indol-3-yli...)
Affinity DataKd:  50nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In DepthDetails PCBioAssay
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty

US Patent
LigandPNGBDBM16673(4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamo...)
Affinity DataKd:  95nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In DepthDetails PCBioAssayDrugBank

TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty

US Patent
LigandPNGBDBM31096(CHEMBL290084 | Staurosporine | cid_451705)
Affinity DataKd:  28nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In DepthDetails PCBioAssay
TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty

US Patent
LigandPNGBDBM4814(CHEMBL535 | N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fl...)
Affinity DataKd:  50nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In DepthDetails PCBioAssayDrugBank

TargetVascular endothelial growth factor receptor 3(Homo sapiens (Human))
Cancer Therapeutics Crc Pty

US Patent
LigandPNGBDBM13534(CHEMBL572878 | N-[4-({4-[(3-methyl-1H-pyrazol-5-yl...)
Affinity DataKd:  1.90E+3nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In DepthDetails PCBioAssay
Displayed 1 to 50 (of 137 total ) | Next | Last >>
Jump to: